Zura Bio (NASDAQ:ZURA) Earns Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. Leerink Partners started coverage on Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective on the stock. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Finally, Chardan Capital cut their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zura Bio currently has an average rating of “Buy” and a consensus price target of $15.80.

Zura Bio Price Performance

NASDAQ ZURA opened at $2.93 on Monday. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The stock has a 50-day simple moving average of $4.16 and a 200 day simple moving average of $4.08.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, analysts predict that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Insider Transactions at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the sale, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This represents a 2.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 22.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Zura Bio

Institutional investors have recently added to or reduced their stakes in the company. Great Point Partners LLC lifted its stake in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after buying an additional 1,884,501 shares during the last quarter. Armistice Capital LLC raised its holdings in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares in the last quarter. Braidwell LP acquired a new stake in Zura Bio during the third quarter worth about $10,040,000. Point72 Asset Management L.P. bought a new position in Zura Bio in the second quarter valued at approximately $8,446,000. Finally, Geode Capital Management LLC lifted its position in shares of Zura Bio by 70.6% during the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after buying an additional 377,545 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.